EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy
Authors
Keywords
-
Journal
Nature Communications
Volume 11, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-11-18
DOI
10.1038/s41467-020-19704-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- ROCplot.org: Validating predictive biomarkers of chemotherapy/hormonal therapy/anti‐HER2 therapy using transcriptomic data of 3,104 breast cancer patients
- (2019) János T. Fekete et al. INTERNATIONAL JOURNAL OF CANCER
- Reduction of Global H3K27me3 Enhances HER2/ErbB2 Targeted Therapy
- (2019) Alison Hirukawa et al. Cell Reports
- Recurrent PPP2R1A Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth
- (2016) Dorien Haesen et al. CANCER RESEARCH
- PP2A Inhibitor PME-1 Drives Kinase Inhibitor Resistance in Glioma Cells
- (2016) Amanpreet Kaur et al. CANCER RESEARCH
- PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2–Targeted Therapies in Breast Cancer
- (2015) Ian J. Majewski et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial
- (2015) Sara A Hurvitz et al. LANCET ONCOLOGY
- Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration
- (2015) Tiziana Triulzi et al. Oncotarget
- PME-1 Modulates Protein Phosphatase 2A Activity to Promote the Malignant Phenotype of Endometrial Cancer Cells
- (2014) E. Wandzioch et al. CANCER RESEARCH
- Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831
- (2014) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
- (2014) Fabrice André et al. LANCET ONCOLOGY
- Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer
- (2012) S. Chandarlapaty et al. CLINICAL CANCER RESEARCH
- The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
- (2012) Christina Curtis et al. NATURE
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
- (2011) Sarat Chandarlapaty et al. CANCER CELL
- EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes -Catenin-Dependent Hepatocarcinogenesis
- (2011) A. S. L. Cheng et al. CANCER RESEARCH
- Clk2 and B56β Mediate Insulin-Regulated Assembly of the PP2A Phosphatase Holoenzyme Complex on Akt
- (2011) Joseph T. Rodgers et al. MOLECULAR CELL
- Context-Specific Regulation of NF-κB Target Gene Expression by EZH2 in Breast Cancers
- (2011) Shuet Theng Lee et al. MOLECULAR CELL
- Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
- (2011) Siyuan Zhang et al. NATURE MEDICINE
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- GOBO: Gene Expression-Based Outcome for Breast Cancer Online
- (2011) Markus Ringnér et al. PLoS One
- B55β-Associated PP2A Complex Controls PDK1-Directed Myc Signaling and Modulates Rapamycin Sensitivity in Colorectal Cancer
- (2010) Jing Tan et al. CANCER CELL
- Identification of PP2A Complexes and Pathways Involved in Cell Transformation
- (2010) A. A. Sablina et al. CANCER RESEARCH
- PP2A Regulatory Subunit PP2A-B′ Counteracts S6K Phosphorylation
- (2010) Katrin Hahn et al. Cell Metabolism
- Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines
- (2009) Y. Kataoka et al. ANNALS OF ONCOLOGY
- An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients
- (2009) Balazs Györffy et al. BREAST CANCER RESEARCH AND TREATMENT
- Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
- (2009) W. Scheuer et al. CANCER RESEARCH
- A PP2A Regulatory Subunit Regulates C. elegans Insulin/IGF-1 Signaling by Modulating AKT-1 Phosphorylation
- (2009) Srivatsan Padmanabhan et al. CELL
- Prognosis of Women With Metastatic Breast Cancer byHER2Status and Trastuzumab Treatment: An Institutional-Based Review
- (2009) Shaheenah Dawood et al. JOURNAL OF CLINICAL ONCOLOGY
- From Promiscuity to Precision: Protein Phosphatases Get a Makeover
- (2009) David M. Virshup et al. MOLECULAR CELL
- Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors
- (2008) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started